US Biopharmaceuticals: ASCO Postmortem on Kura and Eikon: Feedback from KOLs and companies

Research evidence excerpt

US Biopharmaceuticals: ASCO Postmortem on Kura and Eikon: Feedback from KOLs and companies

Accessible version

US Biopharmaceuticals

ASCO Postmortem on Kura and Eikon:

Feedback from KOLs and companies

Industry Overview

Ahead of Kura’s debrief last night—and following ASCO’s conclusion on June 2nd—we 04 June 2026

connected with our KOLs for an in-depth review of the relevant solid tumor presentations Equity

across our coverage universe. Below, we discuss their feedback, along with our takeaways United States

from Kura’s presentation, and the implications on the respective programs. Biopharmaceuticals

KURA: Darli’s broad utility reinforces upside case JasonResearchZemanskyAnalyst

In our view, Kura sharpened the development thesis of darlifarnib (“darli”), reinforced by BofAS

clear investigator enthusiasm and early signals across multiple tumor types and +1jason.zemansky@bofa.com646 855 4280

partnered with different mechanisms (see our darli takes report). At this point, we think Jacqueline Plesset

few would disagree darli has intriguing potential, a view echoed by our KOLs. Rather, we Research Analyst

BofAS

think debate is shifting towards the development pathway—which indications, lines, and +1 646 855 0014

partners offer the most compelling clinical and commercial upside, particularly when jacqueline.plesset@bofa.com

balanced against cost and an evolving landscape. To that end, we view the updated

plans—including newly announced phase 1a/b of darli + RASi daraxonrasib in 2L+ PDAC

and the phase 1b darli + cabozantinib in RCC (data expected ’27)—as logical next steps

capable of positioning darli with meaningful long-term upside. Abbreviations:

KURA: ASCO readthrough highlights proof-of-mechanism 2L: second line

ASCO: American Society of Clinical Oncology